GlaxoSmithKline Pharmaceuticals

3,118.20
+157.70
(5.33%)
Market Cap
50,152.70 Cr
EPS
34.83
PE Ratio
57.17
Dividend Yield
2.50 %
Industry
Healthcare
52 Week High
3,148.00
52 Week Low
1,921.00
PB Ratio
27.08
Debt to Equity
0.01
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from4 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+50.00 %
+50.00 %
Hold
Hold+25.00 %
+25.00 %
Sell
Sell+25.00 %
+25.00 %
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,683.40
#1 4,02,152.50
35.22
#1 49,887.20
12.06
#1 9,648
-18.99
41.26
6,698.00
1,78,846.20
81.14
8,184.00
0.89
1,600
23.05
67.81
1,480.50
1,19,866.20
22.68
26,520.70
14.17
4,155
30.28
47.08
3,175.70
1,07,876.10
55.75
10,785.70
11.59
1,656
10.91
44.11
1,243.20
1,03,547.60
#1 18.35
28,905.40
12.36
5,578
21.14
65.55
2,454.80
1,00,269.00
50.96
10,615.60
19.57
1,942
-10.91
47.23
918.10
91,854.10
19.78
19,831.50
13.82
3,831
-0.19
59.67
1,970.20
90,728.40
27.40
20,141.50
#1 19.94
1,936
#1 112.49
43.32
1,191.20
68,586.90
20.02
29,559.20
17.55
3,169
-0.50
49.79
30,415.00
64,215.40
45.73
6,097.20
10.80
1,201
27.83
49.61
Forecast
Actual
Growth Rate
Revenue Growth
6.68 %
Net Income Growth
-2.90 %
Cash Flow Change
20.19 %
ROE
-4.90 %
ROCE
-3.94 %
EBITDA Margin (Avg.)
6.85 %

Quarterly Financial Results

Quarterly Financials
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Revenue
754
831
871
823
819
1,299
795
803
707
888
834
785
764
964
838
2,132
776
939
826
826
815
985
833
962
850
1,050
985
1,015
Expenses
608
663
688
588
623
688
1,408
602
535
739
611
707
586
678
636
634
596
660
585
618
618
668
751
673
584
689
658
641
EBITDA
145
168
183
236
196
611
-613
201
172
150
223
78
178
286
202
1,497
180
279
241
208
198
318
83
290
266
361
327
374
Operating Profit %
17 %
19 %
17 %
22 %
21 %
22 %
-81 %
22 %
18 %
16 %
23 %
5 %
18 %
27 %
22 %
22 %
20 %
28 %
27 %
22 %
19 %
30 %
7 %
28 %
28 %
32 %
31 %
34 %
Depreciation
11
12
12
14
19
23
18
23
22
22
18
18
18
17
18
15
16
16
16
17
16
18
17
18
16
17
19
15
Interest
0
0
0
0
1
1
3
2
1
1
1
1
1
0
1
0
1
0
0
1
0
0
0
1
0
0
0
1
Profit Before Tax
134
157
171
222
176
587
-634
177
149
127
204
60
160
268
184
1,482
163
262
224
190
181
299
65
271
249
344
308
359
Tax
50
56
57
75
63
85
27
39
38
51
48
45
39
64
34
263
44
69
60
57
49
82
20
76
67
91
78
96
Net Profit
84
101
114
147
114
503
-661
138
111
77
157
14
121
204
150
1,219
119
193
165
133
132
218
46
195
182
253
230
263
EPS in ₹
9.93
5.95
6.71
8.67
6.70
29.68
-39.03
8.15
6.54
4.51
10.26
0.85
7.14
12.06
8.87
71.96
7.04
11.42
9.71
7.41
7.04
12.84
9.89
11.37
10.76
14.67
13.57
15.52

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
3,216
3,055
3,004
3,948
3,911
3,136
3,115
4,633
3,327
3,557
Fixed Assets
123
210
258
325
432
758
387
331
330
321
Current Assets
2,587
2,174
1,674
2,186
2,010
1,775
2,203
3,708
2,494
2,798
Capital Work in Progress
115
268
606
923
1,003
120
13
31
20
14
Investments
0
0
0
0
0
0
0
366
518
813
Other Assets
2,977
2,577
2,140
2,700
2,477
2,257
2,715
3,907
2,458
2,408
Total Liabilities
3,216
3,055
3,004
3,948
3,911
3,136
3,115
4,633
3,327
3,557
Current Liabilities
1,107
579
720
1,600
1,454
1,024
1,355
1,698
1,326
1,525
Non Current Liabilities
280
292
277
290
317
291
282
272
259
254
Total Equity
1,829
2,183
2,007
2,057
2,140
1,821
1,478
2,663
1,741
1,778
Reserve & Surplus
1,744
2,099
1,922
1,973
1,970
1,651
1,309
2,494
1,572
1,608
Share Capital
85
85
85
85
169
169
169
169
169
169

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
21
-0
24
62
-102
6
300
-119
-251
29
Investing Activities
180
499
301
-104
-153
-57
418
-406
808
9
Operating Activities
338
139
234
473
410
491
578
811
484
582
Financing Activities
-497
-638
-511
-307
-358
-428
-696
-524
-1,543
-562

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
3.48 %
4.02 %
4.36 %
4.50 %
4.52 %
DIIs
5.31 %
5.51 %
5.50 %
5.61 %
5.61 %
4.08 %
10.45 %
10.28 %
10.30 %
10.23 %
10.01 %
8.53 %
7.90 %
7.50 %
7.34 %
7.30 %
7.79 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.01 %
0.01 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
11.02 %
10.86 %
10.83 %
10.67 %
10.41 %
10.41 %
10.40 %
10.56 %
10.54 %
10.57 %
10.62 %
11.08 %
11.27 %
11.15 %
10.97 %
10.96 %
10.60 %
Others
8.67 %
8.62 %
8.67 %
8.73 %
8.98 %
10.51 %
4.15 %
4.16 %
4.16 %
4.20 %
4.37 %
5.38 %
2.35 %
2.33 %
2.33 %
2.23 %
2.09 %
No of Share Holders
1,19,951
1,20,476
1,21,445
1,23,480
1,10,141
1,12,964
1,16,651
1,20,127
1,20,415
1,19,032
1,15,266
1,14,663
1,18,994
1,18,515
1,19,228
1,19,625
1,21,885

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 30 35 20 40 30 90 32 32 0.00
Dividend Yield (%) 0.00 2.87 2.7 1.59 2.78 1.8 7.05 1.64 1.11 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
27 Jun 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
27 Jun 2025 2,721.25 2,960.05
30 May 2025 DIVIDEND Dividend
₹ 42.00 /share
30 May 2025 2,721.25 2,960.05
13 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
13 May 2025 2,928.60 2,721.25
14 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
14 Feb 2025 2,077.20 1,998.80
07 Nov 2024 DIVIDEND Dividend
₹ 12.00 /share
07 Nov 2024 2,644.65 2,632.20
29 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
29 Oct 2024 2,630.85 2,644.65
28 Jun 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
28 Jun 2024 2,023.85 2,677.55
31 May 2024 DIVIDEND Dividend
₹ 32.00 /share
31 May 2024 2,023.85 2,593.00
30 Jun 2023 DIVIDEND Dividend
₹ 32.00 /share
30 Jun 2023 1,289.55 1,438.20
26 Jul 2022 ANNUAL GENERAL MEETING Annual General Meeting
NA
26 Jul 2022 1,493.30 1,493.85
08 Jul 2022 DIVIDEND Dividend
₹ 60.00 /share
07 Jul 2022 1,493.30 1,505.90
08 Jul 2022 DIVIDEND Dividend
₹ 30.00 /share
07 Jul 2022 1,493.30 1,505.90
20 Jul 2021 DIVIDEND Dividend
₹ 30.00 /share
19 Jul 2021 1,518.15 1,607.55
13 Sept 2018 BONUS Bonus
1:1
11 Sept 2018 1,726.60 1,724.70

Announcements

Disclosure Under Regulation 30May 16, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 15, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 15, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 15, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 14, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 13, 2025
Appointment Of Parikh & Associates As Secretarial Auditor Of The Company May 13, 2025
100Th Annual General Meeting On 27Th June 2025May 13, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateMay 13, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMay 13, 2025
Announcement under Regulation 30 (LODR)-Dividend UpdatesMay 13, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 13, 2025
Record Date For Final Dividend 30Th May 2025May 13, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 13, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMay 13, 2025
Corporate Action-Board approves DividendMay 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 13, 2025
Outcome Of MeetingMay 13, 2025
Board Meeting Outcome for Outcome Of MeetingMay 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 08, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMay 02, 2025
Disclosure Under Regulation 30Apr 29, 2025
Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotApr 29, 2025
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportApr 29, 2025
Increase In VolumesApr 25, 2025
Increase In VolumesApr 25, 2025
Board Meeting Intimation for Approval Of Audited Financial Results (Standalone & Consolidated) For The Quarter / Year Ended 31St March 2025Apr 17, 2025
Disclosure Under Regulation 30Apr 11, 2025
Disclosure Under Regulation 30Apr 09, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 04, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementApr 04, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMar 31, 2025
Postal Ballot NoticeMar 28, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateMar 26, 2025
Board Meeting Outcome for Change In DirectorateMar 26, 2025
Closure of Trading WindowMar 25, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMar 03, 2025
Disclosure Under Regulation 30Feb 28, 2025
Disclosure Under Regulation 30Feb 28, 2025
Rumour verification - Regulation 30(11)Feb 25, 2025
Rumour verification - Regulation 30(11)Feb 18, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 17, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 17, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 15, 2025
Announcement under Regulation 30 (LODR)-Meeting UpdatesFeb 14, 2025
Integrated Filing (Financial)Feb 14, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 14, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 14, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementFeb 14, 2025
OuctomeFeb 14, 2025

Technical Indicators

RSI(14)
Neutral
56.97
ATR(14)
Volatile
121.05
STOCH(9,6)
Neutral
70.87
STOCH RSI(14)
Overbought
81.26
MACD(12,26)
Bullish
12.85
ADX(14)
Strong Trend
28.88
UO(9)
Bearish
44.68
ROC(12)
Uptrend But Slowing Down
7.27
WillR(14)
Neutral
-40.99

Mutual Fund Holdings

Funding HouseNo of SharesCurrent Holding %1M Change %3M Change %Month
Axis Quant Fund Direct-Growth
71213
2.19%
2.19%
2.19%
Apr 2025
Union Active Momentum Fund Direct-Growth
28346
2.00%
2.00%
2.00%
Apr 2025
Samco Multi Asset Allocation Fund Direct-Growth
14260
1.63%
1.63%
1.63%
Apr 2025
Shriram Multi Sector Rotation Fund Direct-Growth
9900
1.51%
1.51%
1.51%
Apr 2025
Tata BSE Quality Index Fund Direct - Growth
2391
1.47%
1.47%
1.47%
Apr 2025
Samco Flexi Cap Fund Direct - Growth
20000
1.34%
1.34%
1.34%
Apr 2025
Shriram ELSS Tax Saver Fund Direct - Growth
1600
0.99%
0.99%
0.99%
Apr 2025
Shriram Flexi Cap Fund Direct - Growth
4400
0.97%
0.97%
0.97%
Apr 2025
Samco ELSS Tax Saver Fund Direct - Growth
8504
2.29%
-0.62%
2.29%
Apr 2025
JM Midcap Fund Direct - Growth
76716
1.73%
0.55%
0.66%
Apr 2025
Helios Mid Cap Fund Direct-Growth
4886
1.94%
-0.53%
1.94%
Apr 2025
SBI Quant Fund Direct-Growth
56488
0.45%
0.45%
0.45%
Apr 2025
Samco Dynamic Asset Allocation Fund Direct - Growth
6606
0.41%
0.41%
0.41%
Apr 2025
Samco Multi Cap Fund Direct-Growth
12439
1.06%
0.39%
1.06%
Apr 2025
Navi Nifty Midcap 150 Index Fund Direct - Growth
0
0.00%
-0.38%
-0.36%
Apr 2025
Bajaj Finserv Healthcare Fund Direct-Growth
25564
2.44%
0.33%
0.47%
Apr 2025
ITI Pharma and Healthcare Fund Direct - Growth
7906
1.07%
-0.32%
-0.20%
Apr 2025
ITI Mid Cap Fund Direct - Growth
31679
0.84%
-0.30%
-0.25%
Apr 2025
Bajaj Finserv Large and Mid Cap Fund Direct-Growth
101872
1.61%
0.20%
0.47%
Apr 2025
Bajaj Finserv ELSS Tax Saver Fund Direct-Growth
2375
1.43%
0.18%
-0.01%
Apr 2025
Mahindra Manulife Business Cycle Fund Direct - Growth
41937
1.06%
0.17%
0.24%
Apr 2025
Aditya Birla Sun Life ELSS Tax Saver Direct-Growth
868552
1.74%
-0.14%
0.03%
Apr 2025
Bajaj Finserv Multi Cap Fund Direct-Growth
25966
1.27%
0.12%
1.27%
Apr 2025
Aditya Birla Sun Life Pharma & Healthcare Fund Direct-Growth
69775
2.53%
-0.12%
0.07%
Apr 2025
Navi Nifty 500 Multicap 50:25:25 Index Fund Direct-Growth
0
0.00%
-0.09%
-0.09%
Apr 2025

About GlaxoSmithKline Pharmaceuticals

GlaxoSmithKline Pharmaceuticals Limited is an Indian subsidiary of UK-based GSK Plc, engaged in manufacturing, distributing, and trading pharmaceuticals. The company operates in three main product areas: vaccines, specialty medicines, and general medicines. It has manufacturing facilities in Nashik and Thane, with a clinical development center in Bangalore. The company's portfolio includes medicines for various therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease, and respiratory diseases. They also offer a range of vaccines for various diseases. Key brands include Augmentin, Calpol, Shingrix, Nucala, and Trelegy Ellipta. The company has six branch offices and works with 22 contract manufacturing organizations across India. A new manufacturing facility is being developed in Vemgal, Karnataka, with an investment of over Rs 1000 crore.
Chairperson NameRenu S Karnad